The Medication Myth Your Doctor Isn't Allowed to Tell You: Why Your Prescription is Only Half the Story
You leave the doctor's office with a script in hand, a plan in mind, and hope for a cure. You take the pill faithfull...
DACOGEN INJECTION 50mg vial (Decitabine)
$676.33
Active Ingredient : Decitabine
DACOGEN INJECTION 50mg vial (Decitabine) is a targeted therapy designed to treat specific types of blood cancers, helping to improve patient outcomes through effective treatment options.
Reliable shipping
Flexible returns
Dispensing Country : India
DACOGEN INJECTION 50mg vial, containing Decitabine, is a potent chemotherapeutic agent primarily used in the treatment of myelodysplastic syndromes (MDS), including all French-American-British subtypes and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. It is also indicated for the management of acute myeloid leukemia (AML) in adults who are not candidates for induction chemotherapy. Decitabine works by inhibiting DNA methylation, which helps restore normal function to genes that control cell differentiation and proliferation.
Each vial of DACOGEN contains 50mg of Decitabine as a lyophilized powder, which needs to be reconstituted with sterile water before administration. The recommended dosage is 15mg/m², administered by intravenous infusion over a period of 3 hours, repeated every 8 hours for 3 consecutive days. This cycle is typically repeated every 6 weeks, depending on the patient's response and tolerance.
Patients undergoing treatment with DACOGEN may experience side effects such as neutropenia, thrombocytopenia, anemia, fever, nausea, and fatigue. Regular monitoring of blood counts and organ function is essential to manage potential adverse effects effectively. It is crucial to follow the prescribing physician's instructions carefully and report any unusual symptoms immediately.
DACOGEN should be stored at controlled room temperature, away from light and moisture. It is important to handle this medication with care, as it is a cytotoxic agent and can pose risks to healthcare providers and caregivers. Proper disposal procedures should be followed to minimize environmental contamination.
Before starting DACOGEN, patients should inform their healthcare provider about any pre-existing medical conditions, allergies, or medications they are currently taking. Pregnant or breastfeeding women should avoid this medication due to potential risks to the fetus or infant. DACOGEN offers a valuable therapeutic option for patients with MDS and AML, providing hope for improved outcomes and quality of life.
- Decitabine
- Mannitol
- Monobasic potassium phosphate
- Potassium hydroxide
- Hydrochloric acid
DACOGEN INJECTION 50mg vial (Decitabine) is a prescription medication used primarily for the treatment of myelodysplastic syndromes (MDS), including certain types of anemia. It is administered intravenously and should only be used under the supervision of a healthcare professional. Below are detailed instructions on how to use this product safely and effectively.
Before administering DACOGEN, ensure that the vial is intact and the solution is clear. The recommended dosage is 15 mg/m², administered by intravenous infusion over a period of 3 hours. This process should be repeated every 8 hours for 3 consecutive days, which constitutes one cycle. Cycles are typically repeated every 6 weeks, depending on the patient’s response and tolerance to the treatment.
- Reconstitute the 50 mg vial with 10 mL of sterile water for injection. Gently swirl the vial until the powder is completely dissolved. Do not shake vigorously.
- Dilute the reconstituted solution further with 0.9% sodium chloride injection or 5% dextrose injection to achieve a final concentration of 0.1 to 1 mg/mL.
- Administer the diluted solution intravenously over 3 hours using an infusion pump to ensure accurate dosing.
- Monitor the patient closely during and after the infusion for any signs of adverse reactions, such as fever, nausea, or fatigue.
- Dispose of any unused solution properly, following standard procedures for hazardous drugs.
It is crucial to follow the prescribed dosage and administration schedule strictly. Dose adjustments may be necessary based on the patient’s hematologic response and any observed toxicity. Blood counts should be monitored regularly before each cycle to assess the patient’s tolerance and to adjust the treatment plan accordingly.
Patients should be advised to report any unusual symptoms, such as bleeding, infection, or severe fatigue, to their healthcare provider immediately. DACOGEN may lower blood cell counts, increasing the risk of infections and bleeding. Therefore, precautions such as avoiding contact with people who have infections and using extra care to prevent bleeding are recommended.
Storage of DACOGEN should be at room temperature, between 20°C to 25°C (68°F to 77°F). The reconstituted solution can be stored at room temperature for up to 15 minutes or in the refrigerator for up to 7 hours. However, it is best to use the solution immediately after preparation to ensure stability and efficacy.
Always consult the prescribing information and discuss any concerns with a healthcare provider before starting treatment with DACOGEN. Proper administration and monitoring are essential to maximize the benefits of this medication while minimizing potential risks.
You may also like
Our products are sourced directly from brands or authorized distributors.
